Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 28, 2017

Primary Completion Date

June 15, 2018

Study Completion Date

June 15, 2018

Conditions

Hepatic Impairment

Interventions

DRUG

Telotristat Ethyl

Telotristat ethyl (TE) 250 mg (1 x 250-mg tablet), single dose

Trial Locations (3)

Lexicon Investigational Site, Orlando

Lexicon Investigational Site, Miami

Lexicon Investigational Site, San Antonio